Program

13
12

Journal Year Published

4
3
7
3

Author

17
182
174
134
134
125
118
116
114
108
88
86
81
73
56
51
50
43
43
42
34

Category

10
10
5
2

Keyword

3
3
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1

Journal

2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

NCATS Publications

High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.


Jansson KH, Tucker JB, Stahl LE, Simmons JK, Fuller C, Beshiri ML, Agarwal S, Fang L, Hynes PG, Alilin AN, Lake R, Abbey YC, Cawley J, Tice CM, Yin J, McKnight C, Klumpp-Thomas C, Zhang X, Guha R, Hoover S, Simpson RM, Nguyen HM, Corey E, Thomas C, Proia DA, Kelly K


Sci Rep , (8), 17239, 2018.

Article Pubmed

MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.


Yohe ME, Gryder BE, Shern JF, Song YK, Chou HC, Sindiri S, Mendoza A, Patidar R, Zhang X, Guha R, Butcher D, Isanogle KA, Robinson CM, Luo X, Chen JQ, Walton A, Awasthi P, Edmondson EF, Difilippantonio S, Wei JS, Zhao K, Ferrer-Alegre M, Thomas C, Khan J


Sci Transl Med , (10), 2018.

Article Pubmed

Sample image from publication page

Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells.


Ferrer-Alegre M, Gosline SJC, Stathis M, Zhang X, Guo X, Guha R, Ryman DA, Wallace MR, Kasch-Semenza L, Hao H, Ingersoll R, Mohr D, Thomas C, Verma S, Guinney J, Blakeley JO


Sci Data , (5), 180106, 2018.

Article Pubmed

Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.


McKinnon T, Venier R, Yohe M, Sindiri S, Gryder BE, Shern JF, Kabaroff L, Dickson B, Schleicher K, Chouinard-Pelletier G, Menezes S, Gupta A, Zhang X, Guha R, Ferrer-Alegre M, Thomas C, Wei Y, Davani D, Guidos CJ, Khan J, Gladdy RA


Oncogene , 2018.

Article Pubmed

Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma.


Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau D, Guha R, Ferrer-Alegre M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas C


Clin. Cancer Res. , 2017.

Article Pubmed

Sample image from publication page

Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer.


Chen I, Mathews-Greiner L, Li D, Abisoye-Ogunniyan A, Ray S, Bian Y, Shukla V, Zhang X, Guha R, Thomas C, Gryder B, Zacharia A, Beane JD, Ravichandran S, Ferrer-Alegre M, Rudloff U


J Transl Med , (15), 92, 2017.

Article Pubmed

Sample image from publication page

PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.


Gryder BE, Yohe ME, Chou HC, Zhang X, Marques J, Wachtel M, Schaefer B, Sen N, Song YK, Gualtieri A, Pomella S, Rota R, Cleveland A, Wen X, Sindiri S, Wei JS, Barr FG, Das S, Andresson T, Guha R, Lal-Nag M, Ferrer-Alegre M, Shern JF, Zhao K, Thomas C, Khan J


Cancer Discov , 2017.

Article Pubmed

Large-scale pharmacological profiling of 3D tumor models of cancer cells.


Mathews Griner LA, Zhang X, Guha R, McKnight C, Goldlust IS, Lal-Nag M, Wilson K, Michael S, Titus S, Shinn P, Thomas C, Ferrer-Alegre M


Cell Death Dis , (7), e2492, 2016.

Article Pubmed

Sample image from publication page

A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm.


Ceribelli M, Hou ZE, Kelly PN, Huang DW, Wright G, Ganapathi K, Evbuomwan MO, Pittaluga S, Shaffer AL, Marcucci G, Forman SJ, Xiao W, Guha R, Zhang X, Ferrer-Alegre M, Chaperot L, Plumas J, Jaffe ES, Thomas C, Reizis B, Staudt LM


Cancer Cell , (30), 764-778, 2016.

Article Pubmed

Sample image from publication page